Prostate cancer and relation with cardiovascular diseases in hyposexual males

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Corresponding author: M.E. Efremov – Сand.Sc.(Med), Assist. of the urology Dept. of the Kuban State Medical University of the Ministry of Health of the Russian Federation; urologist of the Research Institute – Regional Clinical Hospital № 1 Prof. S.V. Ochapovsky, Krasnodar, Russia; e-mail: efremov.uro@yandex.ru

Introduction. In recent decades, cardiovascular diseases (coronary heart disease, arterial hypertension, arrhythmias, dyslipidemia, etc.) and prostate cancer remain quite frequent causes of incidence and mortality. Previously, the results have been obtained, according to which the development of PCa mainly takes place in men, who are characterized by low sexual activity throughout life, in connection with which there is a need to clarify the relationship between the CVD and PCa.

The purpose of the study. Determine the frequency of the diagnosis of CVD in hyposexual men undergoing brachytherapy.

Materials and methods. The study includes 148 men (group I) aged 68 [64; 72] with the first diagnosis of prostate cancer (PCa) T1C-2CN0M0, subject to brachytherapy, and 99 men (II group) at the age of 67 years [62; 72] The diagnosis of prostate hyperplasia (PH).Diagnostics of PCa and PH was carried out in accordance with the current clinical recommendations of RUA and ROUA. All patients independently filled the Rostov questionnaire at an integral assessment of male sexuality [15]. The diagnosis of related cardiovascular diseases and conditions was carried out according to the clinical recommendations of the RCS. The level of general testosterone in the blood serum was determined on the automatic immunochemistiluminated analyzer «Advia CentAur XP» (Siemens).

Results. Almost half of men (50.7%) from the group had a reduced (≤12.0 nmol/l) level of general blood testosterone and low sexuality. In patients with RPGs, angina pectoris, dyslipidemia, extrasystole and bradyarrhythmia (p <0.05) are reliably more common. And patients with PH significantly more often suffer from common atherosclerosis, atherosclerosis of aorta and coronary arteries, chronic heart failure, tachyarrhythmias, obesity, have acute cerebrovascular accident, stenting of coronary arteries/ aorto-coronary noise (p <0.05). As it turned out, there are no differences in the frequency of coronary heart disease, myocardial infarction, diabetes mellitus, hypertension, atherosclerosis of brachiocephalic arteries for PCa and PH. With angina pectoris, the chances of the availability of PCa than the PH, 2.7 times higher compared to the absence of angina pectoris. With dyslipidemia, the chances of the presence of a diagnosis of prource are higher than 3.8 times. With bradyarrhythms and extrasystoles, the chances of the presence of PCa, not PH, are also significantly increased, but the growth intensity is difficult to accurately assess, since there are no data from the CVD in the group of patients with PCa. In chronic heart failure, the chances that the patient has a PH, not PCa, is 2.8 times higher than the lack of chronic heart failure. The presence of the rest of the CVD (percutaneous stenting of coronary arteries/aorto-coronary bypassing and a history of cerebral circulation in the history of cerebral circulation, atherosclerosis, including aorta and coronary arteries, tachyarrhythms) and obesity increases the chances that the patient will have a diagnosis of PH, and not PCa. As for the level of general testosterone of blood, hyposexual men with PCa do not have its reliable effect on the frequency of SVD.

Conclusion. Identification of the frequency of a wide range of CVD for PCa showed a strong relationship for some and low communication for other CVD. Moreover, the comparison of the connection of the CVD with PCa and PH confirms more differences in these connections than similarities. The study of the mechanisms of the communication of CVD with PCa promising in terms of influence on individual factors of a young man in order to reduce the risks of the development of PCa.

全文:

受限制的访问

作者简介

Anatoly Anosov

Research Institute – Regional Clinical Hospital №1 Prof. S.V. Ochapovsky; Kuban State Medical University of the Ministry of Health of the Russian Federation

Email: vester.orient@gmail.com
ORCID iD: 0009-0002-2126-3136

first year Postgrad. Student of the Dept. of Urology, urologist

俄罗斯联邦, Krasnodar; Krasnodar

Mikhail Efremov

Research Institute – Regional Clinical Hospital №1 Prof. S.V. Ochapovsky; Kuban State Medical University of the Ministry of Health of the Russian Federation

编辑信件的主要联系方式.
Email: efremov.uro@yandex.ru
ORCID iD: 0000-0003-2733-0619

Сand.Sc.(Med), Assist. of the urology Dept., urologist

俄罗斯联邦, Krasnodar; Krasnodar

Vladimir Medvedev

Research Institute – Regional Clinical Hospital №1 Prof. S.V. Ochapovsky; Kuban State Medical University of the Ministry of Health of the Russian Federation

Email: medvedev_vl@mail.ru
ORCID iD: 0000-0001-8335-2578

Dr.Sc. (Med.), PhD, DMS, Full Professor; Head, Dept. of Urology, Deputy Chief Physician for Urology

俄罗斯联邦, Krasnodar; Krasnodar

Stanislav Rаff

Research Institute – Regional Clinical Hospital №1 Prof. S.V. Ochapovsky; Kuban State Medical University of the Ministry of Health of the Russian Federation

Email: staraff@mail.ru
ORCID iD: 0000-0002-5791-4677

Cand. Sci. (Med.), Cardiologist, Head of the Cardiology Department no. 1, Associate Professor, Department of Therapy no. 1, Faculty of Advanced Training and Professional Retraining of Specialists

俄罗斯联邦, Krasnodar; Krasnodar

Mikhail Kogan

Rostov State Medical University

Email: dept_kogan@mail.ru
ORCID iD: 0000-0002-1710-0169

M.D., Dr.Sc.(Med), Full Prof., Honored Scientist of the Russian Federation; Head, Dept. of Urology, Pediatric Urology and Reproductive Health

俄罗斯联邦, Rostov-on-Don

参考

  1. Townsend N, Kazakiewicz D, Lucy Wright F, Timmis A, Huculeci R, Torbica A, Gale CP, Achenbach S, Weidinger F, Vardas P. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol. 2022 Feb;19(2):133-143. doi: 10.1038/s41569-021-00607-3. Epub 2021 Sep 8. PMID: 34497402.
  2. Drapkina O.M., Shalnova S.A., Imaeva A.E., Balanova Yu.A., Maksimov S.A., Muromtseva G.A., Kutsenko V.A., Karamnova N.S., Evstifeeva S.E., Kapustina A.V., Yarovaya E.B., Litinskaya O.A., Pokrovskaya M.S., Efimova I.A., Borisova A.L., Doludin Yu.V., Kontsevaya A.V. Epidemiology of Cardiovascular Diseases in Regions of Russian Federation. Third survey (ESSE-RF-3). Rationale and study design. Cardiovascular Therapy and Prevention. 2022;21(5):3246. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3246. Russian (Драпкина О.М., Шальнова С.А., Имаева А.Э., Баланова Ю.А., Максимов С.А., Муромцева Г.А., Куценко В.А., Карамнова Н.С., Евстифеева С.Е., Капустина А.В., Яровая Е.Б., Литинская О.А., Покровская М.С., Ефимова И.А., Борисова А.Л., Долудин Ю.В., Концевая А.В. Эпидемиология сердечно-сосудистых заболеваний и их факторов риска в регионах Российской Федерации. Третье исследование (ЭССЕ-РФ-3). Обоснование и дизайн исследования. Кардиоваскулярная терапия и профилактика. 2022;21(5):3246. https://doi.org/10.15829/1728-8800-2022-3246).
  3. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, van Leenders GJLH, Liew M, Linares Espinos E, Oldenburg J, van Oort IM, Oprea-Lager DE, Ploussard G, Roberts MJ, Rouvière O, Schoots IG, Schouten N, Smith EJ, Stranne J, Wiegel T, Willemse PM, Tilki D. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024 Aug;86(2):148-163. doi: 10.1016/j.eururo.2024.03.027. Epub 2024 Apr 13. PMID: 38614820.
  4. Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep. 2020 Oct 16;69(41):1473-1480. doi: 10.15585/mmwr.mm6941a1. PMID: 33056955; PMCID: PMC7561091.
  5. Makarov DV, Partin AW. Weighing the risks: prostate cancer versus cardiovascular disease. Rev Urol. 2008 Spring;10(2):171-3. PMID: 18660857; PMCID: PMC2483320.
  6. Wallis CJ, Mahar AL, Satkunasivam R, Herschorn S, Kodama RT, Lee Y, Kulkarni GS, Narod SA, Nam RK. Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation. Urology. 2016 Nov;97:145-152. doi: 10.1016/j.urology.2016.08.002. Epub 2016 Aug 5. PMID: 27502032.
  7. Kao HH, Kao LT, Li IH, Pan KT, Shih JH, Chou YC, Wu ST. Androgen Deprivation Therapy Use Increases the Risk of Heart Failure in Patients With Prostate Cancer: A Population-Based Cohort Study. J Clin Pharmacol. 2019 Mar;59(3):335-343. doi: 10.1002/jcph.1332. Epub 2018 Nov 7. PMID: 30402905.
  8. Ronquist G, Rodríguez LA, Ruigómez A, Johansson S, Wallander MA, Frithz G, Svärdsudd K. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate. 2004 Jan 1;58(1):50-6. doi: 10.1002/pros.10294. PMID: 14673952.
  9. Davey P, Alexandrou K. Assessment and Mitigation of Cardiovascular Risk for Prostate Cancer Patients: A Review of the Evidence. Int J Clin Pract. 2022 May 17;2022:2976811. doi: 10.1155/2022/2976811. PMID: 35685515; PMCID: PMC9158798.
  10. Raisi-Estabragh Z, Cooper J, McCracken C, Crosbie EJ, Walter FM, Manisty CH, Robson J, Mamas MA, Harvey NC, Neubauer S, Petersen SE. Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer. Heart. 2023 Jun 14;109(13):1007-1015. doi: 10.1136/heartjnl-2022-321888. PMID: 37072241; PMCID: PMC10314020.
  11. Navin S, Ioffe V. The association between hypertension and prostate cancer. Rev Urol. 2017;19(2):113-118. doi: 10.3909/riu0758. PMID: 28959148; PMCID: PMC5610361.
  12. Kakkat S, Pramanik P, Singh S, Singh AP, Sarkar C, Chakroborty D. Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections. Int J Mol Sci. 2023 Apr 10;24(8):6984. doi: 10.3390/ijms24086984. PMID: 37108147; PMCID: PMC10138415.
  13. Kogan M.I., Efremov M.E., Medvedev V.L., Anosov A.D., Bratova A.V. Sexual constitution (sexuality) of men with prostate cancer. Urologiia. 2024;6:53–61. https://dx.doi.org/10.18565/urology.2024.6.53-60. Коган М.И., Ефремов М.Е., Медведев В.Л., Аносов А.Д., Братова А.В. Половая конституция (сексуальность) мужчин с раком предстательной железы. Урология. 2024;6:53–61. https://dx.doi.org/10.18565/urology.2024.6.53-60
  14. Kogan MI, Efremov ME, Anosov A D, Medvedev V L, Akhokhov Z M, Sinyavskaya TG, Khmaruk IN. The questionnaire of integrated assessment of male sexuality is a tool for analyzing a man’s sexual functions throughout his life. Urologiia. 2025;2:16–24. https://dx.doi.org/10.18565/urology.2025.2.16-24. Russian (Коган М.И., Ефремов М.Е., Аносов А.Д., Медведев В.Л., Ахохов З.М., Синявская Т.Г., Хмарук И.Н. Опросник интегральной оценки мужской сексуальности – инструмент для анализа сексуальных функций мужчины в течение его жизни. Урология. 2025;2:16–24. https://dx.doi.org/10.18565/urology.2025.2.16-24).
  15. Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A, Shea S. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):869-73. PMID: 9796631.
  16. Henderson BE, Bogdanoff E, Gerkins VR, SooHoo J, Arthur M. Evaluation of cancer risk factors in a retirement community. Cancer Res. 1974 May;34(5):1045-8. PMID: 4823901.
  17. Thompson MM, Garland C, Barrett-Connor E, Khaw KT, Friedlander NJ, Wingard DL. Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol. 1989 Mar;129(3):511-7. doi: 10.1093/oxfordjournals.aje.a115162. PMID: 2916544.
  18. Driver JA, Yung R, Gaziano JM, Kurth T. Chronic disease in men with newly diagnosed cancer: a nested case-control study. Am J Epidemiol. 2010 Aug 1;172(3):299-308. doi: 10.1093/aje/kwq127. Epub 2010 Jul 5. PMID: 20603278; PMCID: PMC2917057.
  19. Thomas JA 2nd, Gerber L, Bañez LL, Moreira DM, Rittmaster RS, Andriole GL, Freedland SJ. Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):576-81. doi: 10.1158/1055-9965.EPI-11-1017. Epub 2012 Feb 7. PMID: 22315364.
  20. Iso H, Ikeda A, Inoue M, Sato S, Tsugane S; JPHC Study Group. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer. 2009 Dec 1;125(11):2679-86. doi: 10.1002/ijc.24668. PMID: 19544528.
  21. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer. 2008 Oct 1;123(7):1693-8. doi: 10.1002/ijc.23715. PMID: 18646186; PMCID: PMC2536746.
  22. Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM Jr, Kristal AR. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2807-13. doi: 10.1158/1055-9965.EPI-09-0472. Epub 2009 Nov 3. PMID: 19887582; PMCID: PMC2877916.
  23. Michaud JE, Billups KL, Partin AW. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol. 2015 Dec;7(6):378-87. doi: 10.1177/1756287215597633. PMID: 26622322; PMCID: PMC4647137.
  24. Morgentaler A. Testosterone and prostate cancer: what are the risks for middle-aged men? Urol Clin North Am. 2011 May;38(2):119-24. doi: 10.1016/j.ucl.2011.02.002. Epub 2011 Apr 13. PMID: 21621078.
  25. Efremov E.A., Krasnyak S.S. Potential risks of testostetone replacement therapy. Experimental and Clinical Urology. 2017;1:90–96. Russian (Ефремов Е.А., Красняк С.С. Возможные риски при терапии тестостероном. Экспериментальная и клиническая урология. 2017;1:90–96).

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bionika Media, 2025